About Index Trending news
Analyze
Top 50 Pricing
Alimera Sciences

Alimera Sciences

Work at Alimera Sciences? Add yourself to this profile

Alimera Sciences

Biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals with a focus on the back of the eye, or retina.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Post-IPO equity
$26,500,000
Post-IPO debt
$35,000,000
Employees

Team size

50+
Locations
HQ
Headquarters
$26,500,000 Post-IPO equity
GlobeNewswire News Room

Alimera Sciences Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock